通冠胶囊对冠心病介入术后病人GMP-140和vWF的影响

The Influence of Tongguan Capsule on Contents of GMP-140 and vWF of Patients with Coronary Heart Disease after PCI

目的 探讨通冠胶囊对冠心病经皮冠状动脉介入治疗(PCI)后病人血浆血小板α颗粒膜蛋白 -14 0 (GMP -14 0 )、血管性假性血友病因子 (vWF)的影响。方法 将 5 2例PCI术后的冠心病病人随机分为治疗组 (西药加通冠胶囊组 )与对照组 (西药组 )。于手术当日、术后 1月及术后 3月检测GMP -14 0、vWF含量。结果 治疗 3月后治疗组GMP -14 0、vWF含量均明显低于对照组 (P <0 .0 1,P <0 .0 5 )。结论 通冠胶囊配合西药治疗能显著降低GMP -14 0、vWF水平 。

Objective To eluciate the influence of Tongguan capsule on GMP-140,von willebrand facetor (vWF) of patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).Methods 52 patients with CHD after PCI were randomizedly divided into Tongguan capsule group(conventional western medicine+Tongguan capsule) and control group (conventional western medicine).The content of GMP-140 ,vWF were analyzed at the right day of PCI , 1 month and 3 months after PCI.Results Both GMP-140 and vWF were significantly lower in Tongguan capsule combined with conventional western medicine than those in the control group after treatment for 3 months (P<0.01,P<0.05).Conclusion The treatment of Tongguan Capsule combined with conventional western medicine could decrease the level of GMP-140 and vWF.Inhibiting the platelet from activating might be the key mechanism of the formula in preventing thrombosis.